Update – 24 November 2023
Consultation extended
You now have until 5pm on 26 January 2024 to send us your submission.
You now have until 5pm on 26 January 2024 to send us your submission.
The Ministry for Primary Industries (MPI) is intending, under section 29 of the Agricultural Compounds and Veterinary Medicines (ACVM) Act 1997, to reassess the conditions of registration applied to all registered vertebrate toxic agents (VTAs). This will be performed sequentially according to the active ingredient, starting with the anti-coagulants and, most immediately, brodifacoum.
MPI has held 2 previous rounds of consultation, the first of which was targeted to industry and the second was a public consultation held in April 2021. These have provided useful feedback on proposed changes to the regulatory controls which were considered as part of this final consultation on the proposed new controls.
As the proposed reassessment of all registered VTA products containing the active ingredient brodifacoum could impact on a wide range of stakeholders, MPI is seeking feedback from all interested parties on the proposed new controls for the manufacture, sale, storage, and use of brodifacoum as a VTA in New Zealand.
We welcome your comments about the proposals and how they will impact the use of these products (as outlined in the discussion document).
Responses to the submissions from the April 2021 brodifacoum public consultation [PDF, 779 KB]
Email your feedback on the discussion document by 5pm on 26 January 2024 to ACVM.Consultation@mpi.govt.nz
While we prefer email, you can send your submission by post to:
ACVM Programmes and Appraisals
Ministry for Primary Industries
PO Box 2526
Wellington 6140
New Zealand.
Also answer these questions:
Note that all, part, or a summary of your submission may be published on this website. Most often this happens when we issue a document that reviews the submissions received.
People can also ask for copies of submissions under the Official Information Act 1982 (OIA). The OIA says we must make the content of submissions available unless we have good reason for withholding it. Those reasons are detailed in sections 6 and 9 of the OIA.
If you think there are grounds to withhold specific information from publication, make this clear in your submission or contact us. Reasons may include that it discloses commercially sensitive or personal information. However, any decision MPI makes to withhold details can be reviewed by the Ombudsman, who may direct us to release it.
MPI uses cookies to improve your experience on our site. By using our website, you accept our use of cookies.